Verbatim response from ChatGPT
Short answer: the active peptide (semaglutide) can be the same, but Wegovy (Novo Nordisk) and compounded semaglutide are very different in regulation, manufacturing, testing, formulation/stability, dosing reliability, clinical evidence, insurance coverage and safety risk. Those differences matter for effectiveness and safety.
Key differences
-
Regulatory approval and evidence
- Wegovy (Novo Nordisk) is FDA‑approved specifically for chronic weight management, with large randomized trials (the STEP program) showing safety and efficacy at the labeled titration and 2.4 mg weekly dose.
- Compounded semaglutide is not FDA‑approved. Compounded versions lack the same clinical trial data proving they work and are safe for weight loss.
-
Manufacturing, quality and testing
- Wegovy is manufactured under strict FDA drug‑manufacturing standards with batch testing for purity, potency and stability.
- Compounded semaglutide is made in compounding pharmacies that vary widely in quality. Some reputable compounding pharmacies follow high standards, but others may not. Compounded products may have inconsistent potency, impurities, or sterility issues.
-
Formulation and device
- Wegovy is supplied in a prefilled pen with a specific formulation and preservatives that support stability and precise dosing.
- Compounded products may be supplied as vials or prefilled syringes and may use different excipients; they often lack the Wegovy pen and may have higher potential for dosing errors or stability problems.
-
Dosing accuracy and titration
- Wegovy’s titration schedule and pens ensure accurate weekly dosing as studied.
- Compounded preparations can increase the risk of under- or overdosing unless produced and measured very carefully.
-
Safety and contamination risk
- Wegovy’s manufacturing minimizes contamination risk.
- Compounded injections carry a greater risk of contamination, especially if sterility procedures are not rigorous.
-
Cost and insurance
- Wegovy is expensive; some insurers deny routine obesity coverage, but Novo Nordisk offers patient support and savings programs.
- Compounded semaglutide is often cheaper out‑of‑pocket. However, it is less likely to be covered by insurance and savings programs, and the lower price may come with greater risk.
-
Legal/regulatory issues
- The FDA discourages compounding copies of approved drugs in many situations. Some states and pharmacies still compound semaglutide, but regulatory status can be complicated and enforcement varies. The FDA has issued warnings about unapproved/counterfeit injectable semaglutide sold online.
Practical advice
- If you want the best‑documented safety, consistent dosing, and manufacturer support, Wegovy (Novo Nordisk) is the preferred choice.
- If cost or availability makes Wegovy impractical, and you’re considering compounded semaglutide:
- Only use a reputable, accredited compounding pharmacy (look for Pharmacy Compounding Accreditation Board (PCAB) accreditation or other strong credentials).
- Ask the pharmacy for a Certificate of Analysis (COA) or assay showing potency and for sterility test results, the compounding date, lot number and storage instructions.
- Get detailed dosing and storage instructions from your prescriber and pharmacist, and confirm the titration schedule.
- Never buy injectable semaglutide from unverified online sellers or social media sources — risk of counterfeit/contaminated product is high.
- Talk with your clinician about approved alternatives (for example, for weight loss there are other prescriptions like Zepbound/tirzepatide [Eli Lilly] or using Ozempic for diabetes under medical guidance), and about monitoring for side effects (GI symptoms, pancreatitis risk signals, gallbladder issues, blood sugar changes).
If you want, I can:
- Summarize the Wegovy dosing/titration schedule,
- Help you find PCAB‑accredited compounding pharmacies in your area,
- Or lay out pros/cons and cost comparisons between Wegovy, Zepbound (tirzepatide), and compounded semaglutide. Which would you like?